Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Brain Neoplasms 2Sarcoma, Ewing 1Prostatic Neoplasms 1Neoplasms 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × alovudine × Clear all
NCT03276676 2024-12-27

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

University of Utah

Phase 1/2 Terminated
10 enrolled 7 charts
CNS

Brain Neoplasms

NCT01065805 2019-08-22

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

AHS Cancer Control Alberta

Phase 1/2 Terminated
94 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡